SecurityRKDA / Arcadia Biosciences, Inc. (039014105)
President and CEORey Eric J.
IndustryAgricultural Chemicals
Institutional Owners3
Institutional Shares159,549 - 3.34%
Common Shares Outstanding4,774,364 shares (as of 2018-06-30)
Institutional Value$ 1,039,000 USD

Institutional Stock Ownership and Shareholders

RKDA / Arcadia Biosciences, Inc. Institutional Ownership

Arcadia Biosciences, Inc. (NASDAQ:RKDA) has 3 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 159,549 shares. Largest shareholders include Sabby Management, LLC, BlackRock Fund Advisors, and BlackRock Investment Management, LLC.
Arcadia Biosciences, Inc. (NASDAQ:RKDA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR Sabby Management, LLC 150,376 121,690 -19.08 3,611 1,004 -72.20
2017-02-10 13F-HR BlackRock Fund Advisors 34,783 35,655 2.51 68 33 -51.47
2018-08-14 13F-HR BARCLAYS PLC 1,000 0 -100.00 24 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 2,204 2,204 0.00 4 2 -50.00

Related News Stories

Arcadia Biosciences' (RKDA) CEO Raj Ketkar on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Good afternoon, and welcome to Arcadia Biosciences' Second Quarter 2018 Earnings Conference Call. Today's presenters will be Raj Ketkar, President and CEO; and Matthew Plavan, CFO. This call is being webcast, and you can refer to the company's press release and slides at arcadiabio.com. (1-0)

Arcadia Biosciences 2018 Q2 - Results - Earnings Call Slides

2018-08-09 seekingalpha
The following slide deck was published by Arcadia Biosciences in conjunction with their 2018 Q2 earnings call. (1-1)

Arcadia Biosciences:  A Speculative Pure-Play In The Genome Editing Agricultural Space

2018-07-16 seekingalpha
I highlight a number of reasons why I've taken a speculative position in RKDA, including commercialization prospects and cash on hand relative to historical burn rates. (5-3)

Arcadia Biosciences: A Micro-Cap Opportunity In Agriculture

2018-05-16 seekingalpha
Recent balance sheet improvements and a diverse pipeline of desirable plant traits for major crops mitigate the risk inherent in the micro-cap space. (12-4)

Arcadia Biosciences' (RKDA) CEO Raj Ketkar on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good afternoon, and welcome to Arcadia Biosciences First Quarter 2018 Earnings Conference Call. Today’s presenters will be Raj Ketkar, President and CEO; and Matt Plavan, CFO. This call is being webcast, and you can refer to the company’s press release and slides at arcadiabio.com. (12-8)

CUSIP: 039014105